Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, sodium valproate as monotherapy stopped seizures in 50% of epileptic children and was most effective in primary generalized and photosensitive epilepsies with notable side effects.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

This study observed that while valproic acid treatment in children led to occasional mild clinical and laboratory side effects, no correlation with drug plasma levels was found.

This study found that venous blood ammonia levels, particularly in patients taking valproate combined with other antiepileptic drugs, were significantly elevated compared to those on valproate alone.

This case report describes a child developing pancreatitis directly linked to valproic acid therapy.

This study examined finasteride, a 5-alpha-reductase inhibitor, for treating a Tourette’s syndrome patient unresponsive to traditional therapy, noting its limited side effects.

This study observed that valproic acid treatment led to a significant reduction in aggressive and impulsive behaviors among patients with acquired brain injury, with varying effects based on cognitive impairment degree; the treatment was generally well-tolerated, though some patients experienced temporary side effects.

This study found that low dose valproate monotherapy in epileptic children commonly leads to side-effects like weight gain and decreased appetite, especially among younger patients.

This study reported that sodium valproate completely stopped epilepsy in 43% of patients and reduced seizures by 50% in 22% of patients who were resistant to other anticonvulsants.

This study reports that alopecia may develop in patients with chronic exposure to high plasma concentrations of valproate, but resolved after dose reduction or treatment discontinuation.

This study presents a case of a 24-year-old man who developed mild transaminitis and rhabdomyolysis within 24 hours of starting valproic acid for seizures, with symptom resolution following drug cessation.

This paper reviews the hair color changes associated with valproic acid treatment, noting only a few reported instances of bleaching or darkening, and reports no new findings.

This review found that valproic acid treatment significantly increases the risk of alopecia compared to other drugs, regardless of dose or treatment duration.

This review indicates that sodium valproate might benefit diabetic peripheral neuropathy patients, but evidence is limited and inconsistent, so it should be reserved for treatment-resistant cases.

This review, drawing on literature and personal experience, suggests that sodium valproate is a safe and effective antiepileptic drug for various epileptic conditions in children and adults, including the elderly.

This study found that sodium valproate effectively stopped or reduced seizures in patients with various types of epilepsy, with best results in absence and myoclonic seizures, though it caused temporary hair loss in some cases.

This study found that both levetiracetam and valproate sodium effectively reduced seizure frequency and duration in patients with refractory epilepsy, but levetiracetam had fewer side effects related to liver enzyme changes.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This case study reports on a 23-month-old child who developed onychomadesis after valproic acid treatment, which resolved on its own without further intervention.

This study highlights that the evidence linking valproic acid to specific genetic variants is limited, unlike other antiseizure medications such as carbamazepine and phenytoin.

In this case report, a 17-year-old male on sodium valproate therapy developed rare longitudinal melanonychia, suggesting sodium valproate can induce nail pigmentation as a side effect.

This study found that sodium valproate effectively controlled petit mal seizures in children resistant to other anticonvulsants but was less effective for other seizure types.

This case report details a 66-year-old male patient who developed eosinophilic pleuro-pericardial effusion likely due to valproic acid toxicity or overdosage, with full recovery observed after medication adjustments at a six-month follow-up.

Sodium valproate can rarely cause skin darkening, which may improve after stopping the drug.

This review discusses valproate-associated hair abnormalities, describing their common and benign nature, and outlines management strategies, though new clinical results are not provided.

This case study describes a 19-year-old female patient who gained 13 kg and experienced hair changes while on valproic acid, and partially lost weight after reducing the dosage, but hair changes persisted.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

This study found that sodium valproate improved seizure control in children with epilepsy, with increased weight gain being the most common side effect reported.

This article discusses leukocytoclastic vasculitis, particularly its triggers, manifestations, and treatments, and reports no new experimental results; the authors highlight valproic acid's association with this condition.